Abstract: A mirror support mechanism includes three first supporting members and three second supporting members. Each first supporting member includes a mirror supporting portion that is in contact with and support a corresponding one of three supported surfaces provided on the supported portion with rotational symmetry of 120 degrees around an optical axis, and two first beam portions connected to both sides of the mirror supporting portion. Each second supporting member includes a supporting portion to which ends of two first beam portions adjacent to each other are connected, the ends being not connected to the mirror supporting portion, and two second beam portions connected to both sides of the supporting portion, an end of the second beam portion not connected to the supporting portion being supported by a structure member provided on the rear side of the reflecting mirror.

Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.

Abstract: The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having ROR? antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.

Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.

Abstract: The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having ROR? antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.

Abstract: The present invention provides a method for producing a 7H-pyrrolo[2,3-d]pyrimidine derivative that is useful as a janus kinase (JAK) inhibitor; an intermediate of the 7H-pyrrolo[2,3-d]pyrimidine derivative; and a method for producing the intermediate. The present invention provides a method for producing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile, which uses a salt of an organic acid and (3S,4R)-3-methyl-1,6-diazaspiro[3.4]octane-1-carboxylic acid benzyl.

Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.

Abstract: The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having ROR? antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.

Abstract: According to one embodiment, a method of manufacturing a semiconductor device includes generating a plasma of a first gas containing a nitrogen gas and an ammonia gas, supplying a second gas containing nitrogen-containing radicals produced by generating the plasma of the first gas, to a substrate, supplying an organic metal gas containing a group III metallic element to the substrate, and forming a group III nitride semiconductor layer on the substrate by the second gas and the organic metal gas.

Abstract: According to one embodiment, a film formation apparatus includes a substrate support member, a first gas supplier disposed above the substrate support member and supplying a first gas, a second gas supplier disposed between the substrate support member and the first gas supplier and supplying a second gas, and a plate member disposed between the first gas supplier and the second gas supplier and having a hole, the plate member defining a plasma generation area between the first gas supplier and the plate member, the plasma generation area generating plasma of the first gas, wherein the hole has a diameter between 0.1 to 2 mm and a depth between 0.1 to 5 mm.

Abstract: An object is to provide a more compact motor-operated valve than conventional ones. The motor-operated valve according to the present disclosure includes a first housing chamber housing a first valve body, a second housing chamber housing a second valve body, and an intermediate chamber interposed therebetween, which are arranged in a line. A shaft is placed to connect the first valve body and the second valve body. The first valve body is fitted into a first fitting portion in the first housing chamber so as to be linearly movable. The second valve body is fitted into a second fitting portion in the second housing chamber so as to be linearly movable. An inside of the first fitting portion and an inside of the second fitting portion communicate with an inside of the intermediate chamber through an air passage provided in the shaft.

Abstract: There is provided a method of efficiently manufacturing purified 1224yd containing 1224yd at a high concentration from a mixture containing 1224yd and a compound that forms an azeotropic composition or an azeotropic-like composition with 1224yd. A manufacturing method of purified 1224yd, includes making a first mixture of 1224yd and a compound (X1) forming an azeotropic composition or an azeotropic-like composition with 1224yd to be brought into contact with a first extraction solvent to obtain purified 1224yd not substantially containing the compound (X1).

Abstract: Disclosed is a blowby gas treatment device for an internal combustion engine with a supercharger, the blowby gas treatment device comprising: a fresh air introduction passage wherein one end of the fresh air introduction passage is connected to an upstream side of the supercharger and the other end is communicated with a crankcase of the internal combustion engine; a first blowby gas passage wherein one end of the first blowby gas passage is connected to a venturi part provided in an upstream side of the supercharger in the intake passage and the other end is communicated with the crankcase; a first check valve being interposed in the fresh air introduction passage and preventing a flow from the crankcase side to the intake passage side; and a second check valve being interposed in the blowby gas passage and preventing a flow from the intake passage side to the crankcase side.

Abstract: The present invention provides a method for producing a 7H-pyrrolo[2,3-d]pyrimidine derivative that is useful as a janus kinase (JAK) inhibitor; an intermediate of the 7H-pyrrolo[2,3-d]pyrimidine derivative; and a method for producing the intermediate. The present invention provides a method for producing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile, which uses a salt of an organic acid and (3S,4R)-3-methyl-1,6-diazaspiro[3.4]octane-1-carboxylic acid benzyl.

Abstract: There is provided a method of efficiently manufacturing purified 1224yd containing 1224yd at a high concentration from a mixture containing 1224yd and a compound that forms an azeotropic composition or an azeotropic-like composition with 1224yd. A manufacturing method of purified 1224yd, includes making a first mixture of 1224yd and a compound (X1) forming an azeotropic composition or an azeotropic-like composition with 1224yd to be brought into contact with a first extraction solvent to obtain purified 1224yd not substantially containing the compound (X1).

Abstract: Disclosed is a blowby gas treatment device for an internal combustion engine with a supercharger, the blowby gas treatment device comprising: a fresh air introduction passage wherein one end of the fresh air introduction passage is connected to an upstream side of the supercharger and the other end is communicated with a crankcase of the internal combustion engine; a first blowby gas passage wherein one end of the first blowby gas passage is connected to a venturi part provided in an upstream side of the supercharger in the intake passage and the other end is communicated with the crankcase; a first check valve being interposed in the fresh air introduction passage and preventing a flow from the crankcase side to the intake passage side; and a second check valve being interposed in the blowby gas passage and preventing a flow from the intake passage side to the crankcase side.

Abstract: An electronic device includes a chip component and an external terminal. The external terminal includes a terminal electrode connection part, a mounting connection part, and a support part. The terminal electrode connection part is arranged to face an end surface electrode part of a terminal electrode of the chip component. The mounting connection part is connectable to a mounting surface. The support part faces one side surface of an element body of the chip component closest to the mounting surface so as to support the one side surface spaced from the mounting surface. A bonding region and a non-bonding region are formed between the terminal electrode connection part of the external terminal and the end surface electrode part of the terminal electrode. The non-bonding region is formed from the terminal electrode connection part to the support part.

Abstract: A compound of formula [I-W]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Abstract: An electronic device includes a chip component and an external terminal. The external terminal includes a terminal electrode connection part, a mounting connection part, and a support part. The terminal electrode connection part is arranged to face an end surface electrode part of a terminal electrode of the chip component. The mounting connection part is connectable to a mounting surface. The support part faces one side surface of an element body of the chip component closest to the mounting surface so as to support the one side surface spaced from the mounting surface. A bonding region and a non-bonding region are formed between the terminal electrode connection part of the external terminal and the end surface electrode part of the terminal electrode. The non-bonding region is formed from the terminal electrode connection part to the support part.

Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.